Biocon Ltd 2017 AR2
The report outlines Biocon Limited's financial and operational performance for the fiscal year 2016-17, highlighting its transition to Indian Accounting Standards (Ind AS). Key achievements include an 18% growth in consolidated revenue to INR 40,787 million, driven by a 43% increase in the Biologics segment and 24% in Branded Formulations. The company successfully launched its first biosimilar Insulin Glargine in Japan and secured a major contract for recombinant human insulin in Malaysia. Biocon also advanced its novel biologics portfolio, including progress on Insulin Tregopil and Itolizumab, while continuing its commitment to social responsibility through healthcare, education, and community development initiatives.
Company: Biocon Ltd
Sector: Manufacturing
Country: India
Year: 2017
Type: AR2
Pages: 190
Back to company
Biocon Ltd
Annual Report
The report outlines Biocon Limited's financial and operational performance for the fiscal year 2016-17, highlighting its transition to Indian Accounting Standards (Ind AS). Key achievements include an 18% growth in consolidated revenue to INR 40,787 million, driven by a 43% increase in the Biologics segment and 24% in Branded Formulations. The company successfully launched its first biosimilar Insulin Glargine in Japan and secured a major contract for recombinant human insulin in Malaysia. Biocon also advanced its novel biologics portfolio, including progress on Insulin Tregopil and Itolizumab, while continuing its commitment to social responsibility through healthcare, education, and community development initiatives.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2017
Reporting Period
Apr 1, 2016 - Mar 31, 2017
Fiscal Year
2017
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Renewable Energy
Employees